Search

Search Constraints

You searched for: Author/Creator Bauer, Lars

Search Results

11. FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE. (June 2019)

12. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Issue 5 (17th January 2018)

13. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. Issue 1 (16th March 2022)

14. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Issue 7 (7th May 2020)

15. P242 CZP improves work and household productivity and social participation over 1 year of treatment in patients with non-radiographic axSpA. (20th April 2020)

16. P284 Certolizumab pegol-treated patients with non-radiographic axSpA demonstrate improvements in sleep quality and other patient reported outcomes. (20th April 2020)

17. Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study. Issue 1 (2nd January 2017)

19. Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study. (March 2021)

20. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study. (November 2017)